Charles E Davis - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Charles E Davis

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

HIV Clinical Trials|November 13, 2009

Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapineAnthony Amoroso, Bruce L Gilliam, Rohit Talwani, et al.

The Journal of Infectious Diseases|April 10, 2004

Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoireJose Bordon, Peter S Evans, Nadia Propp, et al.

AIDS Patient Care and Stds|April 28, 2007

Tenofovir and abacavir combination therapy: lessons learned from an urban clinic populationBruce L Gilliam, Mohammad M Sajadi, Anthony Amoroso, et al.

American Journal of Infection Control|August 5, 2004

The effect of moving to a new hospital facility on the prevalence of methicillin-resistant Staphylococcus aureusNicholas J Vietri, David P Dooley, Charles E Davis, et al.

Human Immunology|July 6, 2010

Impact of age, gender, and race on circulating γδ T cellsCristiana Cairo, Cheryl L Armstrong, Jean Saville Cummings, et al.

The Journal of Infectious Diseases|August 8, 2013

Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1Alonso Heredia, Charles E Davis, Marvin S Reitz, et al.

Pageof 2

Search research articles

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

HIV Clinical Trials|November 13, 2009

Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapineAnthony Amoroso, Bruce L Gilliam, Rohit Talwani, et al.

The Journal of Infectious Diseases|April 10, 2004

Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoireJose Bordon, Peter S Evans, Nadia Propp, et al.

AIDS Patient Care and Stds|April 28, 2007

Tenofovir and abacavir combination therapy: lessons learned from an urban clinic populationBruce L Gilliam, Mohammad M Sajadi, Anthony Amoroso, et al.

American Journal of Infection Control|August 5, 2004

The effect of moving to a new hospital facility on the prevalence of methicillin-resistant Staphylococcus aureusNicholas J Vietri, David P Dooley, Charles E Davis, et al.

Human Immunology|July 6, 2010

Impact of age, gender, and race on circulating γδ T cellsCristiana Cairo, Cheryl L Armstrong, Jean Saville Cummings, et al.

The Journal of Infectious Diseases|August 8, 2013

Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1Alonso Heredia, Charles E Davis, Marvin S Reitz, et al.

Pageof 2